Zhejiang Jolly Pharmaceutical Co Ltd
Zhejiang Jolly Pharmaceutical Co.,LTD engages in the research, production, and marketing of Chinese medicinal products in the People's Republic of China and internationally. It offers Wuling capsule to treat insomnia, amnesia, heart palpitations, lack of energy, lassitude in loin and legs, and giddy tinnitus, as well as deficiency of energy and weak pulse caused by the disharmony of heart and kid… Read more
Zhejiang Jolly Pharmaceutical Co Ltd (300181) - Total Liabilities
Latest total liabilities as of September 2025: CN¥1.46 Billion CNY
Based on the latest financial reports, Zhejiang Jolly Pharmaceutical Co Ltd (300181) has total liabilities worth CN¥1.46 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Zhejiang Jolly Pharmaceutical Co Ltd - Total Liabilities Trend (2007–2024)
This chart illustrates how Zhejiang Jolly Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Zhejiang Jolly Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Zhejiang Jolly Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Trigano SA
LSE:0NX0
|
UK | €1.02 Billion |
|
LG Display Co Ltd
NYSE:LPL
|
USA | $19.08 Trillion |
|
Precision Drilling Corporation
NYSE:PDS
|
USA | $1.14 Billion |
|
Charter Hall Long WALE REIT
PINK:CHLWF
|
USA | $1.67 Billion |
|
Vaisala Oyj
PINK:VAIAF
|
USA | $263.00 Million |
|
Ushio Inc
PINK:UHOIF
|
USA | $117.16 Billion |
|
Hyundai Mar&Fi
KO:001450
|
Korea | ₩45.60 Trillion |
Liability Composition Analysis (2007–2024)
This chart breaks down Zhejiang Jolly Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.86 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.31 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Zhejiang Jolly Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Zhejiang Jolly Pharmaceutical Co Ltd (2007–2024)
The table below shows the annual total liabilities of Zhejiang Jolly Pharmaceutical Co Ltd from 2007 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.17 Billion | +37.44% |
| 2023-12-31 | CN¥853.09 Million | -2.97% |
| 2022-12-31 | CN¥879.19 Million | +14.88% |
| 2021-12-31 | CN¥765.31 Million | +1.98% |
| 2020-12-31 | CN¥750.43 Million | +16.73% |
| 2019-12-31 | CN¥642.86 Million | -11.51% |
| 2018-12-31 | CN¥726.50 Million | +9.73% |
| 2017-12-31 | CN¥662.06 Million | +16.97% |
| 2016-12-31 | CN¥566.00 Million | +36.40% |
| 2015-12-31 | CN¥414.94 Million | +33.96% |
| 2014-12-31 | CN¥309.75 Million | +82.88% |
| 2013-12-31 | CN¥169.38 Million | +7.02% |
| 2012-12-31 | CN¥158.27 Million | -1.08% |
| 2011-12-31 | CN¥159.99 Million | +13.09% |
| 2010-12-31 | CN¥141.47 Million | +7.12% |
| 2009-12-31 | CN¥132.07 Million | +1.00% |
| 2008-12-31 | CN¥130.76 Million | +22.45% |
| 2007-12-31 | CN¥106.79 Million | -- |